The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 401-406

  Schneider, J S ^a   Tinker, J P ^a   Menzaghi, F ^b,c   Lloyd, G K ^b,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ARENA PHARMACEUTICALS   (United States)

^d Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; LEVODOPA; NICOTINE; NICOTINIC AGENT; RECEPTOR SUBTYPE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BETA CHAIN; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; EXPERIMENTAL MODEL; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; REACTION TIME; SPATIAL MEMORY; TASK PERFORMANCE; TIME SERIES ANALYSIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ATTENTION; DOPAMINE AGENTS; MACACA FASCICULARIS; MALE; MEMORY; MEMORY, SHORT-TERM; MODELS, ANIMAL; NICOTINIC AGONISTS; PHENOLS; PYRROLIDINES; RECEPTORS, NICOTINIC; SPACE PERCEPTION;

EID: 0038679483     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.051912     Document Type: Article

References (33)

1. Arnsten AFT and Goldman-Rakic PS (1984) Catecholamines and cognitive decline in aged non-human primates. Ann NY Acad Sci 444:218-234.
2. Boller F, Passafiume D, Keefe NC, Rogers K, Morrow L, and Kim Y (1984) Visuo-spatial impairments in Parkinson's disease: role of perceptual and motor factors. Arch Neurol 41:485-490.
3. Bontempi B, Whelan KT, Risbrough VB, Rao TS, Buccafusco JJ, Lloyd GK, and Menzaghi F (2001) SIB-1553A, (±)-4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther 299:297-306.
4. Brown RG and Marsden CD (1988) "Subcortical dementia": the neuropsychological evidence. Neuroscience 25:363-387.
5. Buccafusco JJ and Jackson WJ (1991) Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
6. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, and Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 115:1701-1725.
7. Cooper JA, Sagar HJ, Jordan N, Harvey NS, and Sullivan E (1991) Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 114:2095-2122.
8. Decker MW and Brioni JD (1997) Neuronal nicotinic receptors: potential treatment of Alzheimer's disease with novel cholinergic channel modulators, in Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations (Brioni JD and Decker MW eds) pp 433-459, Wiley-Liss, Inc., New York.
9. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, and Robbins TW (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 27:1329-1343.
10. Flowers KA and Robertson C (1985) The effect of Parkinson's disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry 48:517-529.
11. Freedman M and Oscar-Berman M (1986) Selective delayed response deficits in Parkinson's and Alzheimer's disease. Arch Neurol 43:886-890.
12. Goldman-Rakic PS and Brown RM (1981) Regional changes in monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 6:187-197.
13. Gotham AM, Brown RG, and Marsden CD (1988) "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 111:299-321.
14. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, and Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 107:394-404.
15. Lees AJ and Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106:257-270.
16. MacDermott AB, Role LW, and Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22:443-485.
17. Menzaghi F, McClure DE, and Lloyd GK (1999) Subtype selective nAChR agonists for the treatment of neurological disorders: SIB-1508Y and SIB-1553A, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 379-394, Wiley-Liss, Inc., New York.
18. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53-83.
19. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, and Robbins TW (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115:1727-1751.
20. Pillon B, Beweer B, and Vidailhet M (1998) Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on strategic processes? Neuropsychologia 36:1-9.
21. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, and Buccafusco JJ (1998) Central nicotinic receptor agonists ABT-418, ABT-089 and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacologia 136:50-58.
22. Reid RT, Sacaan AI, Adams PB, Correa LD, Santori EM, McDonald IA, Lloyd GK, and Rao TS (1997) Pharmacological characterization of SIB-1553A, a novel subtype selective nicotinic acetylcholine receptor (NAChR) agonist. Soc Neurosci Abstr 23:477-517.
23. Roeltgen DP and Schneider JS (1994) Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys. Behav Brain Res 60:115-124.
24. Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534:25-36.
25. Schneider JS, Giardiniere M, and Morain P (2002) Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology 26:176-182.
26. Schneider JS and Kovelowski CJ (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519:122-128.
27. Schneider JS and Roeltgen DP (1993) Delayed matching-to-sample, object retrieval and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 615:351-354.
28. Schneider JS, Tinker JP, Van Velson M, Menzaghi F, and Lloyd GK (1999) Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low dose MPTP-treated monkeys. J Pharmacol Exp Ther 290:731-739.
29. Sharpe MH (1990) Distractibility in early Parkinson's disease. Cortex 26:239-246.
30. Sharpe MH (1992) Auditory attention in early Parkinson's disease: an impairment in focused attention. Neuropsychologia 30:101-106.
31. Taylor AE, Saint-Cyr JA, and Lang AE (1986) Frontal lobe dysfunction in Parkinson's disease. Brain 109:845-883.
32. Terry AV Jr, Risbrough VB, Buccafusco JJ, and Menzaghi F (2002) Effects of (±)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301:284-292.
33. Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, et al. (1999) 4-{[2-(1-Methyl-2-pyrrolidlnyl)ethyl]thio}pheno] hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 42:1684-1686.